Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
UCSD study suggests that combination of APOBEC-related mutagenesis and tumor mutation burden may be used as a biomarker of response to immunotherapy.
Researchers at DFCI analyzed genome-scale loss-of-function datasets and identified adenosine deaminase acting on RNA as a gene dependency in subsets of lung cancer.
Scientists report that two myeloid leukemia cases with FMS-like tyrosine kinase (FLT3) fusions demonstrate mixed features of myelodysplastic and myeloproliferative syndromes; showed sensitivity to FLT3 inhibitors in ex vivo drug screening assays.
CTD2 scientists at Stanford University demonstrated that air-liquid interface patient-derived tumor organoid models retain the original tumor immune cells, enabling testing for personalized immunotherapy in cancer.
Scientists at the Emory University CTD2 Center developed the High-Throughput immunomodulator Phenotypic (HTiP) screening platform to explore PPI inhibitors, as immunomodulators. This screening identified the Inhibitor of Apoptosis Protein (IAP) as anti-tumor immunity enhancers.
CTD2 researchers at Emory University identify novel role for large tumor suppressor 2, LATS2, as a regulator of the ASK1-mediated stress response pathway which may lead to new strategies to control cellular response to stress in normal cells and diseases.
UCSF scientists developed a bioinformatic approach, MAGNETIC, which integrates multi-omic data from cancer patients with pharmacogenomic data from cell lines into a small set of pathway-enriched gene modules. These modules connect tumor and cell line biomarkers and may inform therapeutic targets.
UCSF (1) CTD2 researchers identified a synthetic lethal interaction between EGFR tyrosine kinase inhibitors and Aurora kinase inhibitors in acquired resistant cells. This study suggests combinatorial treatment to prevent treatment resistance with the monotherapies.
CTD2 scientists at Oregon Health and Science University performed genetic and small-molecule screens and identified CSF1R as a novel therapeutic target of acute myeloid leukemia.